Kelowna, British Columbia — October 16, 2025 — Leads & Copy — Rize Oncology Inc., a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, has announced the resignation of Daren Graham as Executive Chairman and interim Chief Executive Officer. P. Gage Jull, a current Director of the Company, has been appointed as the interim Chief Executive Officer.
It is anticipated that Mr. Jull’s appointment will be for a limited period while the Board of Directors evaluates potential candidates to fill the position permanently.
Rize Oncology Inc. is dedicated to the development of STS-201, a small-molecule drug with a unique mechanism of action, currently being evaluated for its potential in treating soft tissue sarcoma and other cancers.
Contact:
P. Gage Jull
416-562-7525
gagejull1@gmail.com
Source: Rize Oncology Inc.
